Abstract:
Objectives: We aimed to assess the risk of incident autoimmune and inflammatory conditions during the post-acute period of COVID-19.
Design: Descriptive network cohort study.
Setting: Electronic health records from the UK and Dutch primary care, Norwegian linked health registry, hospital records of specialist centres in Spain, France and Korea and healthcare claims from Estonia and the USA.
Participants: We followed individuals between September 2020 and the latest available data from day 91 after a SARS-CoV-2 negative test (comparator) or a COVID-19 record (exposed patients, ie assessing patients during the post-acute phase). We further established a reinfection cohort (any further COVID-19 record among the exposed patients). We followed patients until an outcome, end of study period, death, day 365 or an infection (comparator only) or reinfection (exposed patients only).
Main outcome measures: We assessed postural orthostatic tachycardia syndrome (POTS) diagnoses/symptoms, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) diagnoses/symptoms, multi-inflammatory syndrome (MIS) and several autoimmune diseases (rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD) and type 1 diabetes mellitus (T1DM)). Meta-analysed crude incidence rate ratios (IRRs) of outcomes after COVID-19 versus negative testing and after reinfection versus a previous COVID-19 record yield the ratios of respective absolute risks of each assessed outcome. We performed subgroup analyses by age, sex and predominant variant periods.
Results: We included 2 521 812 individuals with a first COVID-19 record, 4 233 145 with a first negative test and 135 551 with a reinfection. Age and sex were largely comparable between exposure groups with a shorter follow-up for the reinfection cohorts. After COVID-19 compared with test-negative patients and equally after reinfection compared with previous COVID-19 patients, we did not observe increased rates for all outcomes and all subgroup analyses. Counts of MIS and JIA were too small for meta-analyses.
Conclusions: In our descriptive meta-analyses of crude IRRs among databases from various countries and settings, we did not observe increased rates of incident POTS, ME/CFS, RA, IBD, SLE and T1DM in COVID-19 versus test-negative or reinfection versus COVID-19 during the first 9 months of the post-acute phase of COVID-19 or reinfection (>90 days postinfection until month 12). Since causal interpretation cannot be made from this study, further causal research is warranted.
Source: Burkard TM, López-Güell K, Català M, Burn E, Delmestri A, Khalid S, Jödicke AM, Dedman D, Oyinlola J, Abellan A, Pérez-Crespo L, Mercadé-Besora N, Duarte-Salles T, Prieto-Alhambra D, Arinze J, Mosseveld M, Kolde R, Meléndez J, López-Blasco R, Martínez Á, Valdivieso B, Delseny D, Mercier G, Kim C, Kim JW, Kostka K, Ramírez-Anguita JM, Mayer MA, Trinh NTH, Nordeng H, Paredes R, Uusküla A, Nishimura A, Loste C, Mateu L, Xie J. Risks of autoimmune and inflammatory post-acute COVID-19 conditions: a network cohort study in six European countries, the USA and Korea. BMJ Public Health. 2026 Jul 24;4(3):e001686. doi: 10.1136/bmjph-2024-001686. PMID: 42516718; PMCID: PMC13404851. https://pmc.ncbi.nlm.nih.gov/articles/PMC13404851/ (Full text)